Natural Peptide PEPITEM Shows Promise in Reducing Arthritic Joint Swelling

New research suggests PEPITEM could offer a significant advancement in the treatment of inflammatory arthritis.

Apr. 13, 2026 at 11:12am

Got story updates? Submit your updates here. ›

A translucent X-ray photograph showing the internal structure of a human joint, with areas of inflammation and damage visible as glowing, ghostly lines against a dark background, conceptually representing the potential of PEPITEM to address joint inflammation and damage in arthritis.An X-ray view of an inflamed joint, highlighting the potential of PEPITEM to reduce swelling and prevent further damage in inflammatory arthritis.Birmingham Today

PEPITEM, a naturally occurring immunopeptide, has demonstrated promising results in both human and animal studies for reducing inflammation and joint damage associated with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Scientists at the University of Birmingham, who discovered PEPITEM, found it could prevent the onset of disease and significantly reduce joint swelling in animal models, with results comparable to current standard treatments.

Why it matters

PEPITEM's potential to restore the body's natural immune regulation process could offer a safer alternative to existing immunosuppressive therapies for arthritis. Early intervention with PEPITEM may prevent irreversible joint damage, while personalized treatment based on individual deficiencies in the Adiponectin-PEPITEM pathway could maximize its effectiveness.

The details

The Adiponectin-PEPITEM pathway plays a crucial role in regulating immune function and the movement of immune cells. In healthy individuals, adiponectin stimulates white blood cells to produce PEPITEM, which then reduces their migration into tissues, preventing an overactive inflammatory response. However, in inflammatory arthritis, this natural regulatory process breaks down, leading to uncontrolled inflammation and joint damage. Researchers found a reduced capacity of white blood cells to respond to adiponectin in patients with suspected inflammatory arthritis, a deficiency that could be restored with PEPITEM supplementation.

  • The recent study was published in Arthritis & Rheumatology in April 2026.

The players

University of Birmingham

The institution where the initial discovery and characterization of the Adiponectin-PEPITEM pathway took place, and where the recent study on PEPITEM's efficacy was conducted.

Professor Helen McGettrick

A researcher at the University of Birmingham who highlighted the potential benefits of PEPITEM over existing immunosuppressive therapies for arthritis.

Got photos? Submit your photos here. ›

What they’re saying

“There could be significant benefits over existing therapies, which are immunosuppressive in otherwise healthy populations. The risk of toxicity from a natural peptide is extremely low, and administration in early disease could reduce reliance on steroids in the earliest phases of rheumatoid arthritis and psoriatic arthritis.”

— Professor Helen McGettrick, Researcher, University of Birmingham

What’s next

The success of PEPITEM in pre-clinical models opens doors for several exciting future trends in arthritis treatment, including early intervention, personalized medicine, combination therapies with existing DMARDs, and exploring its potential in other autoimmune diseases.

The takeaway

PEPITEM's ability to restore the body's natural immune regulation process could provide a safer and more effective alternative to current arthritis treatments, with the potential to prevent irreversible joint damage when administered early in the disease process.